FDA and Homeopathy: Part Two.

Friends, skeptics, and curious consumers, lend me your ears; I come not to
praise homeopathy, but to figure out why the U.S. Food and Drug
Administration (FDA) treats sugar pills and magic water like real drugs
and what, if anything, it plans to do about it.

This “Part Two” look at FDA and homeopathy picks up where the
first act left off: the agency has finally admitted that letting a multi-billion-dollar
homeopathic industry operate in a regulatory gray zone was probably not its
best idea. The market has exploded, safety problems have cropped up, and
the old “hands-off” approach is being replaced with something that sounds
much tougher: a risk-based enforcement policy. At the same time, the
Federal Trade Commission (FTC) has told homeopathic manufacturers that
if they’re going to sell “remedies,” they need evidence that those remedies
actually work.

In classic Science-Based Medicine fashion, let’s dig into what homeopathy
really is, how it ended up with special treatment, what the FDA and FTC are
doing now, and what all of this means for patients who just want to get
better without getting scammed.

What Is Homeopathy and Why Does the FDA Care?

Homeopathy isn’t herbal medicine, vitamins, or “natural” treatments in
general. It’s a specific, 18th-century system built on two big ideas:
“like cures like” and “the more you dilute a substance, the stronger its
effect.” In practice, many homeopathic remedies are diluted so much that
not a single molecule of the original ingredient is likely to remain. At
that point you’re basically taking a very confident sugar pill.

From a modern scientific perspective, homeopathy has a serious evidence
problem. Systematic reviews and meta-analyses have repeatedly found no
reliable effect beyond placebo. Yet homeopathic products are sold right
next to real medicines in U.S. pharmacies, often with packaging that
looks just as official and just as medical. They claim to relieve cold
symptoms, teething pain, flu, allergies, anxiety, and more.

That’s where the FDA comes in. Because homeopathic products are
considered “drugs” under U.S. law, the agency has the authority to regulate
their safety, quality, and claims. Historically, though, it chose to exercise
extraordinary leniency. That leniency is what the current policy changes
are trying slowly, cautiously to unwind.

How Homeopathic Products Fell Into a Regulatory Loophole

The Copeland Amendment and the HPUS

The odd legal status of homeopathy dates back to the 1938 Federal Food,
Drug, and Cosmetic Act. A homeopath and U.S. senator, Royal Copeland,
helped write the law and inserted a special provision: products listed in
the Homeopathic Pharmacopeia of the United States (HPUS) would be
recognized as “official” drugs, alongside those in the standard U.S.
Pharmacopeia.

In theory, this didn’t exempt homeopathic drugs from normal requirements
like proof of safety and efficacy. In practice, however, the FDA treated
them as a separate category that it would deal with “later.” For decades,
homeopathy remained a niche market, and the agency decided that spending
scarce resources on ultra-diluted sugar pellets was not a high priority.

CPG 400.400: The Old Gentlemen’s Agreement

In 1988, the FDA issued Compliance Policy Guide (CPG) 400.400, laying out
the conditions under which homeopathic drugs could be marketed. As long as
a product:

• Was listed in the HPUS,
• Was properly labeled as homeopathic, and
• Was sold over the counter only for “self-limiting” conditions,

the agency generally looked the other way. No premarket approval, no
clinical trials, no meaningful demonstration of benefit.

That “gentlemen’s agreement” worked mostly unnoticed until the market
changed dramatically. Homeopathy grew into a multi-billion-dollar
industry, products started targeting serious conditions, and quality
problems including contamination and toxic levels of ingredients
started triggering safety alerts and recalls. At that point, ignoring
homeopathy stopped being politically and ethically sustainable.

From Hands-Off to “Risk-Based” Enforcement

The 2017 Draft and 2019 Revised Guidance

Around 2015, the FDA finally announced that it would re-evaluate how it
regulates homeopathic drugs. After public hearings and years of internal
debate, the agency released a draft guidance in 2017 explaining a new
risk-based enforcement approach. A revised draft followed in 2019,
and the old CPG 400.400 was withdrawn.

The idea was straightforward: the FDA would treat all homeopathic products
as unapproved drugs which they are but would focus its enforcement
energy where the risk to the public is greatest. In other words, it can’t
shut down the entire industry overnight, but it can prioritize.

The 2022 Final Guidance: What “Risk-Based” Really Means

In December 2022, the FDA issued its final guidance on homeopathic drug
products. Under this framework, the agency still has the authority to
act against any illegally marketed homeopathic drug, but it specifically
targets products that:

• Contain ingredients associated with potentially serious safety concerns,
• Are intended to treat serious or life-threatening diseases,
• Are intended for vulnerable populations (infants, children, pregnant people, older adults, or immunocompromised patients),
• Are contaminated or manufactured with poor quality controls, or
• Are administered in non-oral forms (like injectables, eye drops, or nasal sprays).

In practical terms, that means the FDA is most likely to go after things
like:

• Homeopathic injectables claiming to treat cancer, heart disease, or COVID-19,
• Contaminated or mis-formulated teething remedies that actually contain dangerous amounts of belladonna, and
• Nasal sprays or eye drops that are not sterile or have inconsistent dosing.

The agency has already issued warning letters, seizures, and import alerts
against several manufacturers of homeopathic products that violated these
risk-based priorities. That’s a big shift from the “do nothing” era, even
if it still falls short of what many skeptics would consider true
enforcement of the law.

Where the FTC Fits In: Claims, Ads, and Fine Print

While the FDA focuses on how products are made and whether they’re legally
marketed as drugs, the Federal Trade Commission (FTC) polices how those
products are advertised. In 2016, the FTC issued an Enforcement Policy
Statement on OTC homeopathic drug marketing that basically said:
“Homeopathy doesn’t get a free pass.”

Under that policy, if a company claims a homeopathic product can treat a
health condition, it needs competent and reliable scientific evidence
the same standard used for conventional over-the-counter drugs. If it
doesn’t have that evidence (spoiler: it usually doesn’t), the company must
clearly disclose that:

• There is no scientific evidence that the product works, and
• The product’s claims are based only on homeopathic theories from the 1700s not accepted by most modern medical experts.

In theory, that disclosure should appear prominently on the label and in
ads, not buried in microscopic print. In practice, compliance is uneven,
and shoppers rarely notice or understand the disclaimers. Still, the FTC
policy marks a clear shift: magical thinking is no longer an acceptable
advertising strategy.

When “Harmless” Remedies Aren’t Harmless

Defenders of homeopathy often argue that even if it doesn’t work, it’s
harmless. Unfortunately, the FDA’s experience tells a different story.

Because some homeopathic products aren’t actually highly diluted, they can
contain pharmacologically active amounts of potentially toxic ingredients.
There have been episodes where homeopathic teething tablets contained
dangerous levels of belladonna alkaloids, leading to reports of seizures
and breathing problems in infants. Other products have been contaminated
or poorly manufactured, resulting in inconsistent dosing and unexpected
side effects.

Even when the product itself is physically harmless essentially sugar
there’s another real risk: delay or avoidance of effective care.
Choosing a homeopathic “remedy” instead of proven treatment for asthma,
diabetes, cancer, or serious infections isn’t a cute, quirky lifestyle
choice. It can have life-threatening consequences.

From a science-based perspective, the combination of:

• No demonstrated benefit beyond placebo,
• Documented safety and quality issues, and
• Widespread marketing claims that overpromise and mislead,

is exactly what regulation is supposed to address.

Why Science-Based Medicine Remains Skeptical

Writers and clinicians in the Science-Based Medicine world argue that
homeopathy is not just another complementary therapy that needs a bit of
tidying up around the edges. It’s a system based on ideas that conflict
directly with well-established physics, chemistry, and biology. If the
core claims of homeopathy were true that water has a “memory” of
substances that are no longer present, and that dilution increases
potency entire branches of science would need to be rewritten.

Instead, clinical trials generally show that homeopathic remedies perform
no better than placebo. That doesn’t mean patients feel nothing; placebo
effects are real and can be powerful. It does mean that adding “magic
dilution” to attentive listening, reassurance, and time adds no measurable
therapeutic benefit.

From this viewpoint, the FDA’s risk-based approach is seen as a political
compromise: better than nothing, but still far from genuinely
science-based regulation. All homeopathic products could, in principle,
be required to meet the same standards as any other drug robust evidence
of safety and efficacy or clearly labeled as placebo-level products.
Instead, many remain in a limbo where they look like medicine but are
regulated like a quirky hobby.

What the New Rules Mean for Patients and Practitioners

So where does this leave the average person standing in front of a drug
store shelf?

First, it’s important to understand that the FDA’s final guidance does
not equal approval of homeopathic products. There are currently no
homeopathic drugs formally approved by the FDA. The guidance simply
explains which products the agency is most likely to act against first.

Second, the FTC’s policy means manufacturers can’t just claim whatever
they like. If a label promises relief from a specific disease, the company
is supposed to have solid evidence or be upfront that it does not. As a
consumer, you can look for those disclaimers and treat them as a big,
flashing warning sign.

Third, healthcare professionals need to be ready for more questions.
Patients may assume that if a product is on the shelf and says “drug” on
the label, someone, somewhere has proven it works. Explaining the
regulatory reality that these are unapproved drugs subject to a kind
of triage enforcement can help patients make more informed choices.

Finally, this evolving policy landscape is an opportunity. It’s a chance
to push for the principle that all health products making medical claims
should be held to the same standard of evidence, whether they come from a
lab, a plant, or a 200-year-old theory about water’s memory.

On the Ground: Experiences at the Intersection of FDA Rules and Homeopathy

Policy documents and guidance letters can feel abstract, but they show up
in real life in very concrete ways. To see what “FDA and homeopathy” looks
like outside the Federal Register, it helps to zoom in on the people who
live with the consequences parents, pharmacists, clinicians, and
patients trying to sort out conflicting messages.

Picture a pediatrician’s waiting room during cold and flu season. A tired
parent arrives with a miserable toddler and a box of homeopathic teething
or cold tablets. The packaging is covered in reassuring phrases:
“gentle,” “natural,” “no side effects.” It sits in the same aisle as
FDA-approved children’s medicines. When that pediatrician gently explains
that the product isn’t FDA-approved, that some products in this category
have been recalled for contamination or toxic ingredients, and that the
best available evidence shows no benefit beyond placebo, the parent is
often stunned. “Then why is it on the shelf?” is a very reasonable
question, and it doesn’t have a simple, satisfying answer.

Pharmacists see a different side of the story. They watch as customers
choose a homeopathic flu remedy over an inexpensive generic antiviral or
skip evidence-based allergy medications in favor of high-dilution
pellets. When the FDA issues a warning letter or recall, the pharmacy has
to pull products, post notices, and explain to worried customers why
something marketed as “safe and gentle” is suddenly off the shelves. The
phrase “risk-based enforcement” doesn’t comfort the parent who has already
given the product to their child.

Clinicians who practice science-based medicine also wrestle with how to
talk about homeopathy without alienating patients. Some patients arrive
convinced that homeopathic remedies are “natural” and therefore superior
to “chemicals.” Others have used them for minor, self-limiting problems
(like a week-long cold) and are sure the sugar pellets made all the
difference. Explaining placebo effects, regression to the mean, and
confirmation bias can sound like an attack on the patient’s experience if
it isn’t done carefully and respectfully.

On the flip side, there are patients who feel betrayed when they learn
that the regulatory system quietly tolerated a category of drugs that
never had to prove they work. For them, the FDA’s new guidance looks less
like a bold reform and more like a long-overdue admission that the old
approach failed.

Even among skeptics and science advocates, there are mixed feelings about
the current policies. Some see the risk-based approach as a pragmatic
first step: focus on contaminated products, toxic ingredients, and
vulnerable populations now; push for broader reforms later. Others worry
that this halfway position normalizes homeopathy by treating it as a
legitimate therapy that merely needs some guardrails, rather than as a
pseudoscientific system that shouldn’t be sold as medicine at all.

What these varied experiences have in common is a sense that the
regulatory landscape still doesn’t match what the public assumes. Most
people think “on the shelf” equals “proven to work” and “FDA-approved.”
The reality especially for homeopathic products is much messier.
Closing that gap will require more than new guidance documents. It will
take clearer labeling, stronger consumer education, and an unwavering
commitment to science-based standards for every product that promises to
diagnose, treat, or prevent disease.

Until then, the safest stance for patients is pleasantly simple: if a
product makes big medical claims but can’t back them up with solid
evidence, treat it like any other too-good-to-be-true offer. Whether the
label says “homeopathic,” “natural,” or “gentle,” skepticism is still one
of the best over-the-counter protections you have.